Paradigm Biocapital Advisors LP Janux Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,400,574 shares of JANX stock, worth $136 Million. This represents 3.93% of its overall portfolio holdings.
Number of Shares
2,400,574
Previous 1,564,452
53.45%
Holding current value
$136 Million
Previous $65.5 Million
66.41%
% of portfolio
3.93%
Previous 2.65%
Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
166Shares Held
37.6MCall Options Held
85.3KPut Options Held
654K-
Ra Capital Management, L.P. Boston, MA9.17MShares$520 Million5.81% of portfolio
-
Janus Henderson Group PLC London, X02.52MShares$143 Million0.06% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$133 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.08MShares$118 Million0.17% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.85MShares$105 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.36B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...